Biomea Fusion reports Phase I results for oral GLP-1 agonist BMF-650, showing consistent weight reduction and encouraging tolerability

Biomea Fusion reported results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, showing consistent weight reduction and encouraging tolerability.

Detected & updated continuously · Source: Nebula